http://www.cryocath.com Toronto Stock Exchange Symbol: CYT
MONTREAL, July 2 /PRNewswire-FirstCall/ - CryoCath Technologies Inc. (TSX: CYT), the global leader in cryotherapy products to treat cardiac arrhythmias, today announced the appointment of Frank Vandeputte as Vice President, Europe. Based in CryoCath's new European headquarters in Leiden, The Netherlands, Mr. Vandeputte will be responsible for leading the European business operation. This includes the development and implementation of strategic and operational business plans, with the objective of driving ongoing rapid sales growth of the Company's innovative products in the European market.
Mr. Vandeputte joins CryoCath with more than 20 years of experience in the medical device industry. Most recently, he served as Area Vice President Benelux and Nordic for the Sorin Group, based in Brussels. Prior to that he was Vice President International Marketing with the Sorin Group. Prior to Sorin, he held senior management positions with leading medical device companies, including Baxter International Inc, Becton Dickinson and Guidant Corporation. With Guidant, he has been providing leadership to their European Cardiac Resynchronisation Therapy, Endovascular and Cardiac Surgery business, and served as Country Manager for Germany as well.
"With his proven leadership and medical device industry successes, Frank will be an asset to our European commercial operations. He, and his successful European leadership team, will spearhead the ongoing rapid growth of Arctic Front in Europe," said Jan Keltjens, CryoCath President and CEO. "Additionally, we have now opened our European headquarters in Leiden, the Netherlands. This will allow us to better serve the needs of our expanding customer base in Europe. By establishing a strong European presence and enhancing our management team, we are continuing to execute on our strategy of becoming a leader in atrial fibrillation therapy."
CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.
This press release includes "forward looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.
|SOURCE CryoCath Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved